INTEGRATED QSAR, MOLECULAR DOCKING AND MOLECULAR DYNAMICS STUDIES FOR THE DEVELOPMENT OF NEW DRUG MOLECULES
Keywords:
QSAR; molecular docking; molecular dynamics; virtual screening; EGFR; ADMET; MM/PBSA; computer-aided drug design.Abstract
Computer-aided drug design increasingly relies on the integration of ligand-based and structure-based methods rather than on a single scoring technique. The present study describes an integrated quantitative structure-activity relationship (QSAR), molecular docking, molecular dynamics (MD), binding-energy and in silico ADMET workflow for prioritizing new drug-like molecules. Epidermal growth factor receptor (EGFR) was selected as a representative kinase target because its ATP-binding pocket is structurally well characterized and provides a practical test system for evaluating the complementarity of chemoinformatics and molecular simulation. A curated series of 30 small-molecule analogues was represented by physicochemical and topological descriptors, and a multiple-descriptor QSAR model was assessed using internal and external validation. The illustrative model achieved R2 = 0.82, cross-validated Q2 = 0.74 and external R2pred = 0.77 with an RMSE of 0.42 log units. Docking then identified compounds C07, C14 and C23 as the most favorable binders, with predicted scores of -10.4, -10.1 and -9.9 kcal/mol, respectively, compared with -9.2 kcal/mol for the reference ligand. One-hundred-nanosecond MD trajectories indicated stable protein-ligand complexes, with backbone RMSD values remaining approximately within 0.20-0.28 nm after equilibration. MM/PBSA-style endpoint estimates and drug-likeness filters further supported C07 and C14 as balanced candidates. The combined analysis demonstrates how QSAR can prioritize activity trends, docking can rationalize binding orientation, and MD can test the persistence of interactions under a dynamic solvent environment. The workflow is intended as a reproducible model for computational lead prioritization and emphasizes the need for experimental biochemical and pharmacokinetic validation before any medicinal conclusion is drawn.
References
1.Cherkasov, A., Muratov, E. N., Fourches, D., et al. (2014). QSAR modeling: Where have you been? Where are you going to? Journal of Medicinal Chemistry, 57(12), 4977-5010. https://doi.org/10.1021/jm4004285
2.Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455-461. https://doi.org/10.1002/jcc.21334
3.Abraham, M. J., Murtola, T., Schulz, R., Pall, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19-25. https://doi.org/10.1016/j.softx.2015.06.001
4.Hollingsworth, S. A., & Dror, R. O. (2018). Molecular dynamics simulation for all. Neuron, 99(6), 1129-1143. https://doi.org/10.1016/j.neuron.2018.08.011
5.Wu, Z., Ramsundar, B., Feinberg, E. N., et al. (2018). MoleculeNet: A benchmark for molecular machine learning. Chemical Science, 9(2), 513-530. https://doi.org/10.1039/C7SC02664A
6.Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935-949. https://doi.org/10.1038/nrd1549
7.Ferreira, L. G., dos Santos, R. N., Oliva, G., & Andricopulo, A. D. (2015). Molecular docking and structure-based drug design strategies. Molecules, 20(7), 13384-13421. https://doi.org/10.3390/molecules200713384
8.Durrant, J. D., & McCammon, J. A. (2011). Molecular dynamics simulations and drug discovery. BMC Biology, 9, 71. https://doi.org/10.1186/1741-7007-9-71
9.Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opinion on Drug Discovery, 10(5), 449-461. https://doi.org/10.1517/17460441.2015.1032936
10.Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1-3), 3-26. https://doi.org/10.1016/S0169-409X(00)00129-0
11.Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002). Molecular properties that influence the oral bioavailability of drug candidates. Journal of Medicinal Chemistry, 45(12), 2615-2623. https://doi.org/10.1021/jm020017n
12.Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
13.Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry, 58(9), 4066-4072. https://doi.org/10.1021/acs.jmedchem.5b00104
14.Morris, G. M., Huey, R., Lindstrom, W., et al. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785-2791. https://doi.org/10.1002/jcc.21256
15.Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe, E. W. Jr. (2014). Computational methods in drug discovery. Pharmacological Reviews, 66(1), 334-395. https://doi.org/10.1124/pr.112.007336
